Method for detecting toxic action of oral mucosal interferonotherapy |
|
|
IPC classes for russian patent Method for detecting toxic action of oral mucosal interferonotherapy (RU 2288474):
 Identification of transgenic dna sequences in plant material and products made of the same, oligonucleotide kit and bioarray therefor / 2270254
Invention relates to method for detection of typical marker foreign DNA sequences, usable in plant modification, in transgenic plant materials and products made of the same. Claimed identification method includes carrying out of multiplex polymerase chain reaction on the base of DNA isolated from tested material followed by hybridization of fluorescent labeled reaction products on specialized bioarrays. Hybridization data are registered by control and program complex and identification of foreign genes and regulatory zones thereof in tested material is carried out, and obtained results are quantitatively interpreted.
Method for detecting immunoreactive compounds / 2268471
The present innovation deals with one-stage detection of a bound analyte with a conjugate consisted of an analyte-stereospecific compound (anti-analyte) being covalently conjugated with suspensoid particles of water-insoluble dyestuffs, as coumassi R-250, and/or acridine yellow, and/or acridine orange, and/or 2.4-nitrodiphenyl hydrazine, and/or fluorescein. Application of an anti-analyte with a colored suspensoid label in technology for obtaining conjugates for analysis of one-stage covalent binding leads to considerable simplification of synthesis procedure, increased economy, and reproducibility and higher sensitivity of detection systems. Thus, the innovation enables to improve sensitivity and reliability of stereospecific analysis and optimization of technology to obtain reagents applied in this process being necessary for detection (stereospecific conjugates).
 The method of determining the direction of transport and metabolic rate between mineralized tissue and contacting the biological fluid / 2242007
The invention relates to medicine and can be used in dentistry, trauma, radiology, biochemistry and pathophysiology
 The method for determining the level of circulating autoantibodies in biological fluids / 2240561
The invention relates to medicine, in particular to immunology, and can be used for the diagnosis of autoimmune process
 Method of imaging cell death in the body of a mammal subject in vivo / 2228765
The invention relates to medicine, in particular to radiology
The method of therapeutic effects on the body / 2228531
The invention relates to medicine, namely to immunology, and can be used for the treatment of diseases associated with a dysfunction of the immune system
 The reagent for diagnosing infections caused by puumala virus / 2218571
The invention relates to diagnostics of virus
 Labeled luciferase antibody and a method thereof, a method of performing analysis on specific binding and set for use in the analysis of the specific binding / 2199125
The invention relates to biotechnology, relates to a method of conjugating luciferase with chemical particle, in particular antibody, providing (a) mixing luciferase with one or more components, such as D-luciferin, magnesium ions and ATP, and (b) carrying out the reaction of covalent binding between luciferase and linking reagent using covalently bonding agent, where D - luciferin, magnesium ions and/or adenosine triphosphate present in a quantity sufficient to protect the luciferase activity from inhibition of covalently binding agent
The way to determine the inhibitory effect of substances on the complement / 2195665
The invention relates to medicine, namely to immunology, and relates to a method of determining a direct impact on the functional activity of complement components of various substances, including drugs
 Way assessment authority for the determination of isoenzymes of glutathione s-transferase and a kit for implementing the method / 2154832
The invention relates to medicine, namely to a rapid assay for detecting and/or determining glutathione S-transferring enzyme (GSTs) for use in assessing the condition of the body
Method for detecting immunoreactive compounds / 2268471
The present innovation deals with one-stage detection of a bound analyte with a conjugate consisted of an analyte-stereospecific compound (anti-analyte) being covalently conjugated with suspensoid particles of water-insoluble dyestuffs, as coumassi R-250, and/or acridine yellow, and/or acridine orange, and/or 2.4-nitrodiphenyl hydrazine, and/or fluorescein. Application of an anti-analyte with a colored suspensoid label in technology for obtaining conjugates for analysis of one-stage covalent binding leads to considerable simplification of synthesis procedure, increased economy, and reproducibility and higher sensitivity of detection systems. Thus, the innovation enables to improve sensitivity and reliability of stereospecific analysis and optimization of technology to obtain reagents applied in this process being necessary for detection (stereospecific conjugates).
Identification of transgenic dna sequences in plant material and products made of the same, oligonucleotide kit and bioarray therefor / 2270254
Invention relates to method for detection of typical marker foreign DNA sequences, usable in plant modification, in transgenic plant materials and products made of the same. Claimed identification method includes carrying out of multiplex polymerase chain reaction on the base of DNA isolated from tested material followed by hybridization of fluorescent labeled reaction products on specialized bioarrays. Hybridization data are registered by control and program complex and identification of foreign genes and regulatory zones thereof in tested material is carried out, and obtained results are quantitatively interpreted.
Method for detecting toxic action of oral mucosal interferonotherapy / 2288474
One should daily introduce into oral cavity of inbred mouse BALB/c for about 3-5 d an olive-shaped melted edge of capron fish line of 0.5-2.0 mm diameter impregnated with glycerol-containing preparation of recombinant interferon-α, containing 104-106 IU/ml recombinant human interferon-α, then in a dead mouse it is necessary to determine against an intact mouse the morphofunctional state of hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes to evaluate: the absence of toxic action of oral mucosal interferonotherapy in case of no degenerative alterations in hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes in inbred mouse BALB/c subjected to oral mucosal interferonotherapy; the presence of toxic action of oral mucosal interferonotherapy at availability of degenerative alterations of hepatocytes and/or enterocytes, and/or lymphoid tissue of regional lymph nodes in inbred mouse BALB/c after oral mucosal interferonotherapy. The innovation increases information value of the method suggested.
 Method for determining substances transport intensity changes in prevailing directions between blood and non-mineralized organs / 2297001
Method involves introducing radioisotope to animals and further repeatedly determining radioisotope inclusions percent in blood and in and in non-mineralized organs in given time intervals, calculating relative radio-activity RRA for an animal examined at each time as ratio between radioisotope inclusions percent in non-mineralized organs to radioisotope inclusions percent in blood. Then transport intensity is determined in prevailing directions in each examination time by applying RRA difference factor (DFRRA), calculated as difference between the subsequent and previous RRA values. The received values of DFRRA factor changes are interpreted in terms of intensity time fluctuations and radioisotope transport direction for each organ.
Method for diagnosing estrogen- and progesteron-dependent genitalia abnormalities / 2312354
Method involves determining estradiol- and progesterone receptors concentration in mononuclear cells fraction of peripheral blood. The value being greater than 210 and 2050 receptors per cell, estrogen- and progesteron-dependent genitalia abnormalities are diagnosed, respectively.
 Method of multyanalite immunoassay with use of microparticles / 2339953
On surface of porous membrane apply the reactionary admixture containing analyte, the first binding molecules bound to detecting substance and specific to analyte, the investigated sample and the particles, not capable to pass through the pores of a membrane covered with the second binding molecules, also specific to analyte, incubate an admixture for formation of a biospecific complex, wash an admixture from not bound reagents and register in a regimen of the time permission phosphorescence signals in spectral ranges of the detecting substances corresponding to a constant of time of attenuation of these substances. Determine the required analyte on a parity of measured phosphorescence signals, thus use on two kinds of the first and second binding molecules, each kind of the first binding molecule is bound to two detecting is long luminescing substances, for example chelate of europium and platinaporphyrine which parity of concentration in each first binding molecule is chosen in advance and corresponds to defined analyte.
 Method of multianalytic immune assay with using microparticles / 2379691
Invention refers to biology and medicine, namely to immunodiagnosis. There is offered method of multianalytic immune assay based on immunochemical, genetic and other types of reactions of biospecific binding analyte and ligands. There are mixed various categories of microparticles coated with biospecific reagents for binding of various required analytes and marked with one or more fluorochromes in various concentrations emitting a long-living fluorescence. The analysed sample and biospecific developing reagent marked with a detecting fluorochrome with a short-living fluorescence with its excitation area being outside that of fluorochromes with long-living fluorescence are added to the particle mixture. It is followed with reaction for biospecific complex formation. The prepared biospecific complexes are deposited on a solid-phase carrier. The fluorescence emission of all fluorochromes is excited with emitters in two spectral ranges herewith measuring an amount of long-living fluorescence in a time resolution mode to identify the microparticle and an amount of short-living fluorescence of detecting fluorochrome for measuring concentration of required analytes. Thus the concentration ratio of long fluorescing fluorochromes in microparticles for detecting the same type of analyte is constant, and for determining different types of analytes, the concentration ratio differs at least twice.
 Device and method for detecting flourescent marked biological components / 2390024
Device comprises a measuring cavity for receiving and introducing a fluid sample. The measuring cavity has a set fixed thickness not exceeding 170 micrometres. The measuring cavity has a section fit for acquisition of its image. Within the measuring cavity, there is a dry reagent. The reagent contains as a component, a molecule conjugate with phosphor used for binding with biological components and with all other reacting components. The reacting components are soluble and/or suspended in the fluid sample. The method involves mixing of the reagent with the liquid sample to be introduced in the measuring cavity. A section of the sample in the measuring cavity is exposed to electromagnetic radiation of wavelength corresponding to wavelength of phosphor excitation. Phosphor marked biological components are detected through-thickness of the measuring cavity. Further, numerical analysis of the digital image follows to identify the biological components showing phosphor and to determine amounts of the biological components showing phosphor in the sample. The biological components are discernible on the digital image as fluorescing points emitting electromagnetic radiation of wavelength corresponding wavelength of phosphor emission.
 Method of cell population discrimination and application thereof / 2397494
There is offered a method of discrimination and calculation of at least two populations of biological elements - carriers of specific signs, probably presented in a sample. The method provides the use of three different probes, each of which is specifically fixed with one of the populations of biological elements which are required to be detected. Each probe itself becomes detectable due to its proper marker, and two different markers specified have two emission spectra containing at least one common part (overlapping emission spectra), and the third one has the emission spectrum which essentially contain no common parts with two others (nonoverlapping spectrum).
 Identification of molecules modulating protein-protein interaction / 2476891
Group of inventions refers to methods and systems of analysis based on enzymatic degradation following protein-protein interaction for reporter modulation (activation or inactivation).
|
FIELD: medicine. SUBSTANCE: one should daily introduce into oral cavity of inbred mouse BALB/c for about 3-5 d an olive-shaped melted edge of capron fish line of 0.5-2.0 mm diameter impregnated with glycerol-containing preparation of recombinant interferon-α, containing 104-106 IU/ml recombinant human interferon-α, then in a dead mouse it is necessary to determine against an intact mouse the morphofunctional state of hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes to evaluate: the absence of toxic action of oral mucosal interferonotherapy in case of no degenerative alterations in hepatocytes, enterocytes, lymphoid tissue of regional lymph nodes in inbred mouse BALB/c subjected to oral mucosal interferonotherapy; the presence of toxic action of oral mucosal interferonotherapy at availability of degenerative alterations of hepatocytes and/or enterocytes, and/or lymphoid tissue of regional lymph nodes in inbred mouse BALB/c after oral mucosal interferonotherapy. The innovation increases information value of the method suggested. EFFECT: higher accuracy and efficiency of detection. 5 ex
The invention relates to medicine and can be used to determine the toxic effects of oral mucosal interferonoterapii. There is a method of determining the toxicity of recombinant human leukocyte interferon-α2based on the study of its pyrogenic properties in laboratory animals - including resistant to endotoxin mice SN/ / HeJ. According to a known method mice SN/ / HeJ were administered recombinant human leukocyte interferon-α2in the tail vein and measured rectal temperature every 10-15 minutes. Peak febrile reactions observed in 25-30 minutes after injection. Minimum pyrogenic dose was 7.5×103U on the mouse, the optimal pyrogenic dose of 75×103U mouse (Dinarello Ch.A., Bemheim N.A., G.W. Duff, H.V. Le, T.L. Nagabhushan, Hamilton N.C., Coceanl F. Mechanisms of fever induced by recombinant human interferon // The Journal of clinical investigation. - 1984. - Vol.74, N 3. - P.906-913). The main disadvantage of this method is that it is unsuitable for a comprehensive assessment of the toxicity of orally administered drug intended for local interferonoterapii, due to inadequate oral mucosal interferonoterapii way of introducing drug and uninformative for local interferonoterapii the control of toxic action recombine the nogo human leukocyte interferon-α 2- pyrogenic reactions in mice. There is a method of research resorptive action of liposomal forms of interferon in chronic experiment on Wistar rats. According to a known method the drug was applied to the shorn skin of animals within 10 days, 100 μl (5×103ME). As control was used rats, which appliciable liposomes or saline in the equivalent volume. A day after the last application were conducted physiological examination of animals (recorded weight change and body temperature, heart rate, exploratory behavior in the open field test), biochemical and hematological analysis blood. During the same period were killed rats by an overdose of diethyl ether for pathological studies of internal organs, took tissue samples for histological examination. In blood samples was determined by the hemoglobin content of erythrocytes, leukocytes, platelets, was calculated leukogram. Biochemical investigations included the measurement of intensity of the main types of metabolism and activity of enzymes are markers of the functional state of the liver, kidney, heart (V. Zolin, Agafonova O.A., bells A.A., Danilenko DU, Fedosov L.K., Gamaley YEAR, Omehow CENTURIES, padina In A., Sycheva VI The study of the antiviral activity, pharmacokinetics and toxicity of liposomal forms of recombinant α2binterferon-human external use // Herald of the Russian Academy of medical Sciences. - 2001. No. 5. - P.27-31). The main disadvantage of this method is that it is unsuitable for a comprehensive assessment of the toxicity of orally administered drug intended for local interferonoterapii, due to inadequate oral mucosal interferonoterapii way of introducing drug and uninformative for local interferonoterapii system performance monitoring toxic effects of recombinant human interferon-α2. The basis of the invention is to provide adequate drug interferon for oral mucosal interferonoterapii informative when registering its toxic action. The problem is solved by the fact that according to the claimed method daily for 3-5 days in the oral cavity inbred mouse BALB/c mice injected melted in olive the end of the nylon line with a diameter of 0.5 to 2.0 mm, soaked piaristengasse preparation of recombinant interferon-α2with 104-106IU/ml of recombinant human interferon-α2then we crammed milipedes in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes and evaluate: no toxic effects of oral mucosal interferonoterapii in the absence of inbred mouse BALB/c mice subjected to oral mucosal interferonoterapii, degenerative changes of hepatocytes, enterocytes and lymphoid tissue, regional lymph nodes; the presence of toxic action of oral mucosal interferonoterapii if inbred mouse BALB/c mice subjected to oral mucosal interferonoterapii, degenerative changes of hepatocytes and/or enterocytes, and/or lymphoid tissue, regional lymph nodes. As a result of our research were the most sensitive to the action of oral mucosal interferonoterapii animals - mice of BALB/c; defined in sensitive animals are the most reactive organs and tissues for this method of introducing the selected recombinant interferon-α2; the first set of informative criteria toxicity oral mucosal interferonoterapii; developed a device for the implementation of oral mucosal interferonoterapii in mice; defined the limits of variation of doses piaristengasse of recombinant interferon-α2for the study namirah of BALB/c. The inventive method of determining toxicity oral mucosal interferonoterapii is new and are not described in literature. The technical result of the claimed invention is the provision of an adequate drug interferon for oral mucosal interferonoterapii informative when registering its toxic action. The invention is illustrated in the following examples, showing the ability to ensure adequate drug interferon for oral mucosal interferonoterapii informative when registering its toxic action. Example 1. Inbred mouse BALB/c daily for 3 days in the oral cavity drove melted in olive the end of the nylon line with a diameter of 0.5 mm, soaked piaristengasse preparation of recombinant interferon-α2with 104IU/ml of recombinant human interferon-α2then I hammered the mouse was determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes. Found that in mice, after interferonoterapii was absent degenerative changes of hepatocytes, enterocytes and lymphoid tissue, regional lymph nodes. In accordance with what was ustanavlivaetsya toxicity oral mucosal interferonoterapii. Example 2. Inbred mouse BALB/c mice daily for 4 days in the oral cavity drove melted in olive the end of the nylon line with a diameter of 1.5 mm, soaked piaristengasse preparation of recombinant interferon-α2with 105IU/ml of recombinant human interferon-α2then I hammered the mouse was determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoidei tissue, regional lymph nodes. The mouse after interferonoterapii established the presence of degenerative changes of the enterocytes. In accordance with what was established toxicity oral mucosal interferonoterapii. Example 3. Inbred mouse BALB/c mice daily for 5 days in the oral cavity drove melted in olive the end of the nylon line with a diameter of 1.5 mm, soaked piaristengasse preparation of recombinant interferon-α2with 105IU/ml of recombinant human interferon-α2then I hammered the mouse was determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes. The mouse after interferonoterapii established the presence of degenerative changes of hepatocytes. In accordance with what has been installed is but the presence of the toxic effects of oral mucosal interferonoterapii. Example 4. Inbred mouse BALB/c mice daily for 5 days in the oral cavity drove melted in olive the end of the nylon line with a diameter of 2 mm, soaked piaristengasse preparation of recombinant interferon-α2with 105IU/ml of recombinant human interferon-α2then I hammered the mouse was determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes. The mouse after interferonoterapii established the presence of degenerative changes of lymphoid tissue, regional lymph nodes. In accordance with what was established toxicity oral mucosal interferonoterapii. Example 5. Inbred mouse BALB/c mice daily for 5 days in the oral cavity drove melted in olive the end of the nylon line with a diameter of 2 mm, soaked piaristengasse preparation of recombinant interferon-α2with 106IU/ml of recombinant human interferon-α2then I hammered the mouse was determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes. The mouse after interferonoterapii established the presence of degenerative changes hepatocyte is, enterocytes and lymphoid tissue, regional lymph nodes. In accordance with what was established toxicity oral mucosal interferonoterapii. The method of determining the toxicity of oral mucosal interferonoterapii, characterized by the fact that daily for 3-5 days in the oral cavity inbred mouse BALB/c mice injected melted in olive the end of the nylon line with a diameter of 0.5 to 2.0 mm, soaked piaristengasse preparation of recombinant interferon-α2with 104-106IU/ml of recombinant human interferon-α2then I hammered the mouse is determined in comparison with the intact mouse morphofunctional state of hepatocytes, enterocytes, lymphoid tissue, regional lymph nodes and evaluate: no toxic effects of oral mucosal interferonoterapii in the absence of inbred mouse BALB/c mice subjected to oral mucosal interferonoterapii, degenerative changes of hepatocytes, enterocytes and lymphoid tissue, regional lymph nodes, the presence of toxic action of oral mucosal interferonoterapii if inbred mouse BALB/c mice subjected to oral mucosal interferonoterapii, degenerative changes of hepatocytes or enterocytes, and/or lymph is ne tissue, regional lymph nodes.
|